Endpoints News

The "decade of ADCs" continues, and they're expected to become the backbone of cancer care, as AstraZeneca, Kelun-Biotech and Merck Group take the stage at #ESMO25 https://lnkd.in/eHCPyEyi

RAPT, Jeyou are gearing up for a Phase 3 trial after promising mid-stage results in urticaria. https://lnkd.in/e8GZATqZ

Novartis is looking to expand Pluvicto to earlier prostate cancer but questions remain. https://lnkd.in/eYWEUtVv

Alphamedix – a radiopharmaceutical developed by Sanofi and Orano – shines at #ESMO25 after it announced positive mid-stage trial results for a rare cancer. https://lnkd.in/eWAz5GXR

NewLimit, the anti-aging startup co-founded by Coinbase CEO Brian Armstrong, has raised another $45 million from new investors like Eli Lilly's VC arm and S32. The capital carries a valuation cap of $1.6 billion, which acts like “a market signal in a given direction,” NewLimit president and co-founder Jacob Kimmel said in an interview discussing the company’s potential future valuation. That’s nearly double NewLimit’s Series B valuation of $810 million My latest for Endpoints News talks with Kimmel about the latest research progress that drove the raise, coming just five months after its $130M Series B, and what's next for the ambitious company working on partial cell reprogramming: https://lnkd.in/eQJnbmX4

There are promising signs for AI-designed drugs: Iambic Therapeutics shared at #ESMO25 encouraging results in humans for its lead cancer candidate. https://lnkd.in/euZVMdmf

In this week’s Peer Review: Boehringer Ingelheim names Vani Manja global obesity leader, and ex-AbbVie Philip Kym steps in as Calico’s head of drug discovery. Read the full job update: https://lnkd.in/eNdqgxHE

President Trump announced on Thursday announced a new 'most favored nation' deal that secures what he called “massive discounts" on EMD Serono’s fertility drugs. https://lnkd.in/ekDexJEB

As Summit Therapeutics' ivonescimab nears an FDA filing, experts see promise for PD-1xVEGF bispecifics in colorectal cancer — but in different cancers than the original PD-1 drugs. https://lnkd.in/g4kmJmiH

Health tech is taking center stage — from wearables to RWE shaping pharma’s future. Join us Nov. 6 for online sessions in the morning, then meet us in person for a reception at NYC’s Book Club Bar. Seats are limited — reserve your spot now: https://lnkd.in/g5UBmDZW